# Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors

Source: https://onco.cc/trials/nct05055908/  
OnCo record `nct05055908` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of pemetrexed and pembrolizumab in lung cancer, run by Hunan Province Tumor Hospital, now recruiting.

## Summary

Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors is a phase 3, interventional study registered as NCT05055908 by Hunan Province Tumor Hospital, with a registry enrolment figure of 12000 participants, started 2021-10-01 and due to reach its primary completion in 2025-07-01. Interventions recorded: Pemetrexed plus Pembrolizumab; Pembrolizumab; Pemetrexed. Conditions listed: Lung Cancer. Primary outcome: Correlation between Adverse events (AEs) and gene profile. Lung eligibility wording from the registry: "Histologically or cytologically confirmed lung cancer". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: BECOME
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05055908
- Phase: 3
- Setting: Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors With or Without Chemotherapy
- Sponsor: Hunan Province Tumor Hospital
- Enrolled: 12000

## Sources

- ClinicalTrials.gov NCT05055908: https://clinicaltrials.gov/study/NCT05055908

## Connected records

- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05055908.json